Developer docs
API playgroundTry for free, no card

Search company profiles

InVitria

Full company profile

uuid0008dqn

Namestring
InVitria
Legal namestring
InVitria, Inc.
Websiteurl
invitria.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

InVitria is a privately held US biotechnology company that develops and manufactures recombinant, animal-origin-free proteins used as cell culture supplements, media components, and injectable biologic excipients. The company was founded in 2006 in Junction City, Kansas, with corporate origins tracing to Applied Phytologics (1993) and Ventria Bioscience (2002), and operates an ISO 9001:2015-certified, cGMP-compliant bioprocessing facility in Junction City with additional commercial offices in Cambridge, Massachusetts (opened December 2023) and Rotterdam, Netherlands (opened October 2024).

The company's core technology is the proprietary ExpressTec platform, a rice grain-based expression system for recombinant proteins that has been in continuous commercial production since 1998. The product portfolio spans recombinant human serum albumin (Cellastim S, Exbumin, Optibumin 20, Optibumin 25), recombinant human transferrin (Optiferrin), recombinant human holo-lactoferrin (Lacromin), recombinant human lysozyme (Lysobac), recombinant human IL-2 (OptiLeukin 2), recombinant human LIF (OptiKine), insulin-transferrin supplements (ITS, ITSE, ITSE+A), and a chemically defined VERO media (OptiVERO). Exbumin is the only recombinant human serum albumin approved as an excipient in an FDA- and EMA-approved injectable biologic (Merck's ERVEBO Ebola vaccine).

InVitria sells through a hybrid model combining direct enterprise sales with distribution via Fisher Scientific, VWR, and the Labviva procurement platform. Pricing is unit-based, tiered by grade (RUO vs cGMP) and volume, with published unit prices ranging from approximately $48 to $14,800 and quote-based pricing for commercial-scale GMP supply. The company serves 1,000+ active customers across 40+ countries, with 300+ customer clinical programs supported in cell therapy, gene therapy, vaccine production, antibody production, and final formulation applications. It is led by founder and CEO Scott E. Deeter.

Short descriptiontext

InVitria develops and manufactures recombinant, animal-origin-free proteins for cell culture, biomanufacturing, and injectable biologic formulation using its proprietary ExpressTec rice grain expression platform, serving 1,000+ customers across cell therapy, gene therapy, vaccine, and biopharmaceutical sectors globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersJunction City, United States
HQ citystring
Junction City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
recombinant proteins, cell culture media, animal-origin-free reagents, biopharmaceutical manufacturing, bioprocessing supplements
Industry1 code
PRIMARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Bioprocessing Reagents
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Recombinant Protein Product Sales
TypeOne Time License
Description

InVitria generates revenue through direct sales of recombinant, animal-origin-free proteins including recombinant human serum albumin (Cellastim S, Optibumin, Exbumin), recombinant human transferrin (Optiferrin), recombinant human lactoferrin (Lacromin), recombinant human lysozyme (Lysobac), insulin-transferrin supplements (ITS, ITSE, ITSE+A), OptiVERO complete media, and OptiLeukin 2 (recombinant IL-2). Products are sold at various scales from research to GMP commercial volumes with tiered pricing based on volume and grade.

invitria.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Pricing details13 tiers
1Exbumin® – Recombinant human albumin excipient
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$950.00 – $8,170.00

invitria.com
2ITS Animal-Free™ – Blood-free cell culture media supplement
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$47.88 – $400.97

invitria.com
3ITSE Animal-Free® – Blood-free cell culture media supplement
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$57.00 – $477.39

invitria.com
4ITSE+A™ – Blood-free cell culture media supplement
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$72.15 – $561.75

invitria.com
5Lacromin® – Recombinant human holo-lactoferrin
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$840.00 – $7,500.00

invitria.com
6OptiLeukin™ 2 – Recombinant human interleukin-2
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Contact for pricing (custom quotation)

invitria.com
7OptiVERO®
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$198.50

invitria.com
8Cellastim® S – Recombinant human albumin
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$548.00 – $4,349.00

invitria.com
9Optibumin® 20 – Recombinant human albumin
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$1,660.00 – $14,800.00

invitria.com
10Optibumin® 25 – Recombinant human albumin
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$785.00

invitria.com
11Optiferrin® – Recombinant human transferrin
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$351.72 – $2,177.16

invitria.com
12OptiKine™ LIF – Leukemia Inhibitory Factor
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$5,200.00

invitria.com
13Lysobac® – Recombinant human lysozyme
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$299.25 – $2,677.50

invitria.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 11 records shown
1ExpressTec
Description

Proprietary recombinant protein expression platform that uses rice grain as the production host for recombinant proteins, enabling elimination of animal and human-derived components, high expression levels, scalability, and consistent product quality across batches.

invitria.com
+10 more records
Core offering1 text field

InVitria develops and manufactures recombinant, animal-origin-free proteins for cell culture, biomanufacturing, and final formulation using its proprietary ExpressTec rice grain-based expression platform. The portfolio includes recombinant human serum albumin (Cellastim S, Optibumin 20/25, Exbumin), recombinant human transferrin (Optiferrin), recombinant human holo-lactoferrin (Lacromin), recombinant human lysozyme (Lysobac), recombinant human IL-2 (OptiLeukin), LIF (OptiKine), insulin-transferrin supplements (ITS, ITSE, ITSE+A), and a chemically defined complete VERO medium (OptiVERO), supplied at research and cGMP commercial grades to biopharmaceutical manufacturers in cell and gene therapy, vaccine production, and antibody manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Up to 2x cumulative recovery of infectious lentiviral vector across downstream processing using Optibumin 25
+5 more records
Product and service14 records
1Cellastim S
CategoryRecombinant Human Albumin
Description

Recombinant human serum albumin (rHSA) for cell culture and biomanufacturing, produced animal-origin-free and chemically defined, used in antibody production including CHO mAb processes and other biomanufacturing workflows.

2Exbumin
CategoryRecombinant Human Albumin Excipient
Description

Recombinant human serum albumin excipient, the only rHSA approved as an excipient in FDA- and EMA-approved injectable biologics (Merck's ERVEBO Ebola vaccine), used in final formulation of injectable biologics, viral vaccine stabilization, and cell therapy cryopreservation.

3Optibumin 20
CategoryRecombinant Human Albumin
Description

Recombinant human serum albumin (20%) for cell culture, biomanufacturing, and downstream processing stabilization in viral vector and protein production workflows.

4Optibumin 25
CategoryRecombinant Human Albumin
Description

Recombinant human serum albumin (25%) used in lentiviral vector downstream processing (up to 2x cumulative recovery of infectious lentiviral vector), reduced-DMSO MSC cryopreservation (1-2.5% DMSO), and other biomanufacturing applications.

5Optiferrin
CategoryRecombinant Human Transferrin
Description

Recombinant human transferrin for managing iron in cell culture, used in serum-free and chemically defined cell culture media for antibody production and other biomanufacturing.

6Lacromin
CategoryRecombinant Human Lactoferrin
Description

Recombinant human holo-lactoferrin for biomanufacturing and immune-related cell culture applications.

7ITS Animal-Free
CategoryInsulin-Transferrin Supplement
Description

Blood-free cell culture media supplement (insulin, transferrin, selenium) for serum-free and chemically defined cell culture workflows.

8ITSE Animal-Free
CategoryInsulin-Transferrin Supplement
Description

Blood-free cell culture media supplement (insulin, transferrin, selenium, ethanolamine) using recombinant transferrin for chemically defined cell culture.

9ITSE+A
CategoryInsulin-Transferrin Supplement
Description

Blood-free cell culture media supplement (insulin, transferrin, selenium, ethanolamine, plus additional component) for chemically defined cell culture.

10Lysobac
CategoryRecombinant Human Lysozyme
Description

Recombinant human lysozyme for bioprocessing, diagnostics, and life sciences research.

11OptiLeukin 2
CategoryRecombinant Human Interleukin
Description

Recombinant human interleukin-2 produced animal-origin-free for immune cell culture, providing high purity and consistency for T-cell, NK, Treg, TIL, and gamma-delta T-cell expansion in cell therapy manufacturing.

12OptiKine LIF
CategoryRecombinant Cytokine
Description

Recombinant Leukemia Inhibitory Factor for stem cell culture, including maintenance of pluripotency in iPSC and ES cell workflows.

13OptiVERO
CategoryBlood-Free Complete Media
Description

Pre-formulated, serum-free, chemically defined complete medium optimized for VERO cell expansion and viral vaccine production, supporting higher viable cell densities and improved virus production in flask and bioreactor formats.

14Custom Cell Culture Media Development
CategoryMedia Formulation Services
Description

Custom cell culture media formulation services using InVitria's recombinant protein component library, supporting customer-specific biomanufacturing and downstream workflow requirements.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

InVitria joined the NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT), a collaborative research initiative focused on advancing cell manufacturing technologies for therapeutic applications.

invitria.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

InVitria and Cellevate partnered on vaccine manufacturing to develop scalable, defined upstream solutions for vaccine manufacturing using InVitria's recombinant proteins and Cellevate's cell culture platforms.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

InVitria products available through Fisher Scientific for customers whose institutional procurement systems require ordering through established supplier channels.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

InVitria products available through VWR for customers ordering research-scale products alongside other laboratory supplies through existing distributor accounts.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Labviva procurement platform integration enables customers with Ariba, Coupa, Oracle, and Jaggaer systems to integrate InVitria supplier listings into their existing purchasing workflows.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic collaboration for scaling allogeneic disc cell therapy biomanufacturing using InVitria recombinant protein components.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CDMO and bioprocessing supplier offering cell culture media, custom media development, and recombinant protein production services. Comparable to InVitria in cell/gene therapy manufacturing inputs and bioprocess solutions.

TypeDirect peer
Description

Major plasma-derived human serum albumin and plasma fractionation supplier (Albutein/Albucel). Competes with InVitria's rHSA products by offering established plasma-derived alternatives for cell culture and final formulation excipient applications.

TypeBroad incumbent
Description

Bioprocessing equipment and consumables supplier including cell culture media, recombinant albumin (via Albumedix acquisition), and bioprocess solutions. Direct competitor in recombinant albumin and broader bioprocessing inputs.

TypeBroad incumbent
Description

Broad bioprocessing supplier offering cell culture media, supplements, and process development services. Overlaps with InVitria across cell culture supplements, recombinant proteins, and cell therapy manufacturing consumables as part of a much wider portfolio.

TypeDirect peer
Description

Plasma-derived albumin and plasma fractionation supplier (Alburx, Alburex). Competes with InVitria's recombinant albumin in pharmaceutical and cell culture applications where plasma-derived HSA is the incumbent.

TypeEmerging player
Description

Bioprocessing-focused supplier of proteins, chromatography, and process analytics including growth factors and recombinant products used in cell and gene therapy manufacturing. Overlaps with InVitria in bioprocess inputs for advanced therapy manufacturing.

TypeBroad incumbent
Description

Largest life sciences supplier with Gibco cell culture media, recombinant proteins, and bioproduction products. Competes broadly with InVitria across cell therapy, gene therapy, and vaccine production reagent categories.

TypeDirect peer
Description

Plasma protein biopharmaceutical manufacturer producing AlbuRx/Albumin (Human) plasma-derived HSA. Directly competes with InVitria in the albumin excipient and cell culture supplement markets.

9Albumedix (Sartorius)
TypeDirect peer
Description

Direct competitor in recombinant human serum albumin for biopharmaceutical applications; now part of Sartorius, offering Recombumin rHSA used as excipient in cell culture and formulation. Competes head-to-head with InVitria's Cellastim, Optibumin, and Exbumin.

TypeEmerging player
Description

Life sciences supplier offering GMP-grade cytokines (including recombinant IL-2), recombinant proteins, and cell culture reagents. Comparable to InVitria's OptiLeukin and broader cytokine portfolio for immune cell culture applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InVitria

Bioprocessing Reagentsinvitria.com

InVitria develops and manufactures recombinant, animal-origin-free proteins for cell culture, biomanufacturing, and injectable biologic formulation using its proprietary ExpressTec rice grain expression platform, serving 1,000+ customers across cell therapy, gene therapy, vaccine, and biopharmaceutical sectors globally.

What InVitria does

InVitria is a privately held US biotechnology company that develops and manufactures recombinant, animal-origin-free proteins used as cell culture supplements, media components, and injectable biologic excipients. The company was founded in 2006 in Junction City, Kansas, with corporate origins tracing to Applied Phytologics (1993) and Ventria Bioscience (2002), and operates an ISO 9001:2015-certified, cGMP-compliant bioprocessing facility in Junction City with additional commercial offices in Cambridge, Massachusetts (opened December 2023) and Rotterdam, Netherlands (opened October 2024).

The company's core technology is the proprietary ExpressTec platform, a rice grain-based expression system for recombinant proteins that has been in continuous commercial production since 1998. The product portfolio spans recombinant human serum albumin (Cellastim S, Exbumin, Optibumin 20, Optibumin 25), recombinant human transferrin (Optiferrin), recombinant human holo-lactoferrin (Lacromin), recombinant human lysozyme (Lysobac), recombinant human IL-2 (OptiLeukin 2), recombinant human LIF (OptiKine), insulin-transferrin supplements (ITS, ITSE, ITSE+A), and a chemically defined VERO media (OptiVERO). Exbumin is the only recombinant human serum albumin approved as an excipient in an FDA- and EMA-approved injectable biologic (Merck's ERVEBO Ebola vaccine).

InVitria sells through a hybrid model combining direct enterprise sales with distribution via Fisher Scientific, VWR, and the Labviva procurement platform. Pricing is unit-based, tiered by grade (RUO vs cGMP) and volume, with published unit prices ranging from approximately $48 to $14,800 and quote-based pricing for commercial-scale GMP supply. The company serves 1,000+ active customers across 40+ countries, with 300+ customer clinical programs supported in cell therapy, gene therapy, vaccine production, antibody production, and final formulation applications. It is led by founder and CEO Scott E. Deeter.

InVitria firmographics

Firmographics
Name
InVitria
Legal name
InVitria, Inc.
Website
https://invitria.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
InVitria develops and manufactures recombinant, animal-origin-free proteins for cell culture, biomanufacturing, and injectable biologic formulation using its proprietary ExpressTec rice grain expression platform, serving 1,000+ customers across cell therapy, gene therapy, vaccine, and biopharmaceutical sectors globally.
Ownership category
akta.pro rank

InVitria industry classification

Industry
Product category
Bioprocessing Reagents
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Recombinant proteins
  • Cell culture media
  • Animal-origin-free reagents
  • Biopharmaceutical manufacturing
  • Bioprocessing supplements

Where InVitria is headquartered

Location

Headquarters

HQ city
Junction City
HQ country
United States
HQ region
North America

Offices3 records

Markets served

InVitria business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Recombinant Protein Product Sales: InVitria generates revenue through direct sales of recombinant, animal-origin-free proteins including recombinant human serum albumin (Cellastim S, Optibumin, Exbumin), recombinant human transferrin (Optiferrin), recombinant human lactoferrin (Lacromin), recombinant human lysozyme (Lysobac), insulin-transferrin supplements (ITS, ITSE, ITSE+A), OptiVERO complete media, and OptiLeukin 2 (recombinant IL-2). Products are sold at various scales from research to GMP commercial volumes with tiered pricing based on volume and grade.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goExbumin® – Recombinant human albumin excipient
Unit PricingPay-as-you-goITS Animal-Free™ – Blood-free cell culture media supplement
Unit PricingPay-as-you-goITSE Animal-Free® – Blood-free cell culture media supplement
Unit PricingPay-as-you-goITSE+A™ – Blood-free cell culture media supplement
Unit PricingPay-as-you-goLacromin® – Recombinant human holo-lactoferrin
Unit PricingPay-as-you-goOptiLeukin™ 2 – Recombinant human interleukin-2
Unit PricingPay-as-you-goOptiVERO®
Unit PricingPay-as-you-goCellastim® S – Recombinant human albumin
Unit PricingPay-as-you-goOptibumin® 20 – Recombinant human albumin
Unit PricingPay-as-you-goOptibumin® 25 – Recombinant human albumin
Unit PricingPay-as-you-goOptiferrin® – Recombinant human transferrin
Unit PricingPay-as-you-goOptiKine™ LIF – Leukemia Inhibitory Factor
Unit PricingPay-as-you-goLysobac® – Recombinant human lysozyme

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

InVitria product offering

Product offering

Core offering

InVitria develops and manufactures recombinant, animal-origin-free proteins for cell culture, biomanufacturing, and final formulation using its proprietary ExpressTec rice grain-based expression platform. The portfolio includes recombinant human serum albumin (Cellastim S, Optibumin 20/25, Exbumin), recombinant human transferrin (Optiferrin), recombinant human holo-lactoferrin (Lacromin), recombinant human lysozyme (Lysobac), recombinant human IL-2 (OptiLeukin), LIF (OptiKine), insulin-transferrin supplements (ITS, ITSE, ITSE+A), and a chemically defined complete VERO medium (OptiVERO), supplied at research and cGMP commercial grades to biopharmaceutical manufacturers in cell and gene therapy, vaccine production, and antibody manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

  • ExpressTec: Proprietary recombinant protein expression platform that uses rice grain as the production host for recombinant proteins, enabling elimination of animal and human-derived components, high expression levels, scalability, and consistent product quality across batches.
  • Cellastim S
  • Exbumin
  • Optibumin
  • Optiferrin
  • OptiVERO
  • OptiLeukin
  • Lacromin
  • Lysobac
  • ITSE Animal-Free
  • ITS Animal-Free

Products and services

  • Cellastim S Recombinant human serum albumin (rHSA) for cell culture and biomanufacturing, produced animal-origin-free and chemically defined, used in antibody production including CHO mAb processes and other biomanufacturing workflows.
  • Exbumin Recombinant human serum albumin excipient, the only rHSA approved as an excipient in FDA- and EMA-approved injectable biologics (Merck's ERVEBO Ebola vaccine), used in final formulation of injectable biologics, viral vaccine stabilization, and cell therapy cryopreservation.
  • Optibumin 20 Recombinant human serum albumin (20%) for cell culture, biomanufacturing, and downstream processing stabilization in viral vector and protein production workflows.
  • Optibumin 25 Recombinant human serum albumin (25%) used in lentiviral vector downstream processing (up to 2x cumulative recovery of infectious lentiviral vector), reduced-DMSO MSC cryopreservation (1-2.5% DMSO), and other biomanufacturing applications.
  • Optiferrin Recombinant human transferrin for managing iron in cell culture, used in serum-free and chemically defined cell culture media for antibody production and other biomanufacturing.
  • Lacromin Recombinant human holo-lactoferrin for biomanufacturing and immune-related cell culture applications.
  • ITS Animal-Free Blood-free cell culture media supplement (insulin, transferrin, selenium) for serum-free and chemically defined cell culture workflows.
  • ITSE Animal-Free Blood-free cell culture media supplement (insulin, transferrin, selenium, ethanolamine) using recombinant transferrin for chemically defined cell culture.
  • ITSE+A Blood-free cell culture media supplement (insulin, transferrin, selenium, ethanolamine, plus additional component) for chemically defined cell culture.
  • Lysobac Recombinant human lysozyme for bioprocessing, diagnostics, and life sciences research.
  • OptiLeukin 2 Recombinant human interleukin-2 produced animal-origin-free for immune cell culture, providing high purity and consistency for T-cell, NK, Treg, TIL, and gamma-delta T-cell expansion in cell therapy manufacturing.
  • OptiKine LIF Recombinant Leukemia Inhibitory Factor for stem cell culture, including maintenance of pluripotency in iPSC and ES cell workflows.
  • OptiVERO Pre-formulated, serum-free, chemically defined complete medium optimized for VERO cell expansion and viral vaccine production, supporting higher viable cell densities and improved virus production in flask and bioreactor formats.
  • Custom Cell Culture Media Development Custom cell culture media formulation services using InVitria's recombinant protein component library, supporting customer-specific biomanufacturing and downstream workflow requirements.

Quantifiable outcome

  • Up to 2x cumulative recovery of infectious lentiviral vector across downstream processing using Optibumin 25
  • +5 more outcomes

Companies that use InVitria

Customer profile

Named customers3 records

Segments6 records

Ideal customer profiles5 records

InVitria technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

Feature4 records

InVitria partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT)coreStrategic or Co-development PartnerInVitria joined the NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT), a collaborative research initiative focused on advancing cell manufacturing technologies for therapeutic applications.
  • CellevatecoreStrategic or Co-development PartnerInVitria and Cellevate partnered on vaccine manufacturing to develop scalable, defined upstream solutions for vaccine manufacturing using InVitria's recombinant proteins and Cellevate's cell culture platforms.
  • Fisher ScientificcoreChannel Partner/ Reseller/ DistributorInVitria products available through Fisher Scientific for customers whose institutional procurement systems require ordering through established supplier channels.
  • VWRcoreChannel Partner/ Reseller/ DistributorInVitria products available through VWR for customers ordering research-scale products alongside other laboratory supplies through existing distributor accounts.
  • LabvivacoreChannel Partner/ Reseller/ DistributorLabviva procurement platform integration enables customers with Ariba, Coupa, Oracle, and Jaggaer systems to integrate InVitria supplier listings into their existing purchasing workflows.
  • DiscGenicsminorStrategic or Co-development PartnerStrategic collaboration for scaling allogeneic disc cell therapy biomanufacturing using InVitria recombinant protein components.

Scale indicators7 records

Recent moves11 records

Expansion highlights7 records

InVitria competitors and assessment

Company assessment

Broad incumbents

  • Lonza: Global CDMO and bioprocessing supplier offering cell culture media, custom media development, and recombinant protein production services. Comparable to InVitria in cell/gene therapy manufacturing inputs and bioprocess solutions.
  • Sartorius: Bioprocessing equipment and consumables supplier including cell culture media, recombinant albumin (via Albumedix acquisition), and bioprocess solutions. Direct competitor in recombinant albumin and broader bioprocessing inputs.
  • Cytiva (Danaher): Broad bioprocessing supplier offering cell culture media, supplements, and process development services. Overlaps with InVitria across cell culture supplements, recombinant proteins, and cell therapy manufacturing consumables as part of a much wider portfolio.
  • Thermo Fisher Scientific: Largest life sciences supplier with Gibco cell culture media, recombinant proteins, and bioproduction products. Competes broadly with InVitria across cell therapy, gene therapy, and vaccine production reagent categories.

Direct peers

  • Grifols: Major plasma-derived human serum albumin and plasma fractionation supplier (Albutein/Albucel). Competes with InVitria's rHSA products by offering established plasma-derived alternatives for cell culture and final formulation excipient applications.
  • CSL Behring: Plasma-derived albumin and plasma fractionation supplier (Alburx, Alburex). Competes with InVitria's recombinant albumin in pharmaceutical and cell culture applications where plasma-derived HSA is the incumbent.
  • Octapharma: Plasma protein biopharmaceutical manufacturer producing AlbuRx/Albumin (Human) plasma-derived HSA. Directly competes with InVitria in the albumin excipient and cell culture supplement markets.
  • Albumedix (Sartorius): Direct competitor in recombinant human serum albumin for biopharmaceutical applications; now part of Sartorius, offering Recombumin rHSA used as excipient in cell culture and formulation. Competes head-to-head with InVitria's Cellastim, Optibumin, and Exbumin.

Emerging players

  • Repligen: Bioprocessing-focused supplier of proteins, chromatography, and process analytics including growth factors and recombinant products used in cell and gene therapy manufacturing. Overlaps with InVitria in bioprocess inputs for advanced therapy manufacturing.
  • Bio-Techne: Life sciences supplier offering GMP-grade cytokines (including recombinant IL-2), recombinant proteins, and cell culture reagents. Comparable to InVitria's OptiLeukin and broader cytokine portfolio for immune cell culture applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

InVitria social profiles

Digital presence

InVitria financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InVitria leadership team

Management profile

Number of profiles

Profiles8 records

InVitria funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InVitria M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InVitria

What does InVitria do?

InVitria develops and manufactures recombinant, animal-origin-free proteins for cell culture, biomanufacturing, and final formulation using its proprietary ExpressTec rice grain-based expression platform. The portfolio includes recombinant human serum albumin (Cellastim S, Optibumin 20/25, Exbumin), recombinant human transferrin (Optiferrin), recombinant human holo-lactoferrin (Lacromin), recombinant human lysozyme (Lysobac), recombinant human IL-2 (OptiLeukin), LIF (OptiKine), insulin-transferrin supplements (ITS, ITSE, ITSE+A), and a chemically defined complete VERO medium (OptiVERO), supplied at research and cGMP commercial grades to biopharmaceutical manufacturers in cell and gene therapy, vaccine production, and antibody manufacturing.

Is InVitria a public or private company?

InVitria is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was InVitria founded?

InVitria was founded in 2006. It employs 11 to 50 people.

Where is InVitria based?

InVitria is headquartered in Junction City, United States, in the North America region.

How does InVitria make money?

One revenue line is on record: recombinant Protein Product Sales.

Who are InVitria's main competitors?

Broad incumbents on record are Lonza, Sartorius, Cytiva (Danaher) and Thermo Fisher Scientific. Direct peers are Grifols, CSL Behring, Octapharma and Albumedix (Sartorius). Emerging players are Repligen and Bio-Techne.

Does InVitria have an API?

No public API is recorded for InVitria.

What industry is InVitria in?

InVitria's product category is Bioprocessing Reagents. Its primary akta.pro industry code is HLAAAJAI, Bioprocess Consumables & Reagents (resins, membranes, media components, buffers). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooThe Seeds of Unrestricted WarfareA retired Air Force general argues the Chinese Communist Party employs unrestricted warfare, citing a 1999 thesis and InVitria's patent theft. A former InVitria scientist filed a matching patent, costing the company millions in legal fees. The author urges U.S. leaders to counter this strategy.BioSpaceInVitria Presents New Data at ASGCT 2026 on Recombinant Human Serum Albumin for Higher Lentiviral Vector Titers and Improved Cell Therapy ManufacturingInVitria will present new data on recombinant human serum albumin at ASGCT 2026, highlighting improved lentiviral vector titers and cell therapy manufacturing. The data show up to 40% reduction in DMSO during cryopreservation and better T cell viability. The company also notes its albumin platform is used in approved injectable medicines.GlobeNewswireInVitria Showcases Exbumin® and Optibumin® 25 at IPEC Excipient World: Biologics Summit: Recombinant Human Serum Albumins Already Used in On-Market Approved BiologicsInVitria will showcase its recombinant human serum albumin products at the IPEC Excipient World Biologics Summit in Nashville, May 4–6, 2026. Its rHSA has been used in approved injectables, including Merck's ERVEBO Ebola vaccine, and offers Exbumin and Optibumin 25 formulations.EIN PresswireWho Leads the Human Serum Albumin Market and How They CompeteCSL Limited led global human serum albumin sales in 2024 with a 6% market share, according to a market report. The top 10 players held 34% of revenue, and companies are investing in recombinant albumin innovations like InVitria's Optibumin 25.BioSpaceInVitria Showcases Exbumin® and Optibumin® 25 at IPEC Excipient World: Biologics Summit: Recombinant Human Serum Albumins Already Used in On-Market Approved BiologicsInVitria will showcase its recombinant human serum albumin products Exbumin and Optibumin 25 at the IPEC Excipient World Biologics Summit in Nashville, May 4-6, 2026. The company highlights that its rHSA is already used in approved biologics, including Merck's ERVEBO Ebola vaccine, and offers lyophilized and liquid formats for injectable use.PR NewswireGlobal Recombinant Cell Culture Supplements Market: Focus on Recombinant Supplement Products, Applications, and Region - Analysis and Forecast: 2018 to 2028BIS Research published a market analysis report projecting the global recombinant cell culture supplements market to grow from $230.5 million in 2017 to $788.6 million by 2028, driven by benefits including superior purity, consistency, safety profile, and cost-effectiveness over animal-derived supplements. North America led the market in 2017, with the U.S. contributing approximately 93% of the regional share, while the Asia-Pacific region is expected to witness the highest growth rate during the forecast period. The report identifies key players including Thermo Fisher Scientific, Merck KGaA, and STEMCELL Technologies among the competitive landscape.PrwebInVitria Announces New Media Formulation ServiceInVitria, a division of Ventria Bioscience, launched a media formulation service at BIO-Europe in Berlin, offering animal-free cell culture media. The service uses its proprietary ExpressTec technology to produce eight recombinant proteins and supplements, with performance equivalent to animal-based formulations. The company also received funding from the Bill & Melinda Gates Foundation for its platform.